 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 935888-69-0 |
| Molecular formula(MF) | C25H32N4O7S |
| Molecular Weight(MW): | 532.61 |
| Alias |
| In vitro | DMSO | 100 mg/mL (187.75 mM) |
|---|---|---|
| Water | <1 mg/mL | |
| Ethanol | <1 mg/mL |
| Description | Oprozomib (ONX 0912) is an orally bioavailable inhibitor for CT-L activity of 20S proteasome β5/LMP7 with IC50 of 36 nM/82 nM. Phase 1/2. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro |
The anti-MM activity of Oprozomib is associated with activation of caspase-8, caspase-9, caspase-3, and PARP, as well as inhibition of migration of MM cells and angiogenesis. [2] |
||||
| In vivo | Oprozomib is demonstrated an absolute bioavailability of up to 39% in rodents and dogs. It is well tolerated with repeated oral administration at doses resulting in >80% proteasome inhibition in most tissues and elicited an antitumor response in multiple human tumor xenograft and mouse syngeneic models [1]. |